Pharmacologic Inhibition of Cardiac Stem Cell Senescence

Cesselli, Daniela; Caragnano, Angela; Bergamin, Natascha; Zanon, Veronica; Finato, Nicoletta; Livi, Ugolino; Beltrami, Carlo Alberto; Beltrami, Antonio Paolo

doi:10.5772/33732

Cited by 1 publication

(1 citation statement)

References 84 publications

(160 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, we and others have demonstrated that CSC obtained from failing hearts are characterized by cellular senescence processes and functional impairment [107][108][109], thus suggesting that effectiveness of autologous CSC transplantation could be further improved if we are able to understand and reverse the mechanisms that, in chronic heart failure, impairs the resident CSC reservoir [110][111][112]. Moreover, regenerative treatments that rely on paracrine mechanisms could be less effective in very sick patients, due to the dysfunction of resident CSC.…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

Cardiac Resident Stem Cells: Work (Still) in Progress

Beltrami¹,

Cesselli

Beltrami³

2013

J Stem Cell Res Ther

View full text Add to dashboard Cite

Nine years after the existence of resident Cardiac Stem Cells was first demonstrated, and despite the fact that we are right now evaluating the preliminary and promising results of the first phase I clinical trials, our understanding of the mechanisms responsible for cardiac regeneration is still partial and the ability to take advantage of it for therapeutic purposes can be considered still rudimentary. However, the worldwide urgency of developing new regenerative therapeutic strategies to reverse the progression of advanced heart failure is funneling a multidisciplinary effort aimed at better comprehending the biological pathways governing cardiac regeneration. Therefore, in this paper we are critically reviewing the novel scientific evidences regarding: the multiplicity of stem cell populations hosted in the heart; the mechanisms regulating the cardiac embryonic development, such as the epithelial to mesenchymal transition, that may play a part in pathology too; the instructive micro-environmental factors acting within the Cardiac Stem Cell niche and the information gained from clinical trials. Hopefully the consideration of all these aspects will yield potential new targets and more effective strategies for cardiovascular regenerative therapies.

show abstract